1-12 of 12
Beate Klimm
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group

Clinical Trials & Observations
Dennis A. Eichenauer, Indra Thielen, Heinz Haverkamp, Jeremy Franklin, Karolin Behringer, Teresa Halbsguth, Beate Klimm, Volker Diehl, Stephanie Sasse, Achim Rothe, Michael Fuchs, Boris Böll, Bastian von Tresckow, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2014) 123 (11): 1658–1664.
https://doi.org/10.1182/blood-2013-07-512657
Published: 2014
Includes: Supplemental data
Journal Articles

Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients

Michaela Rancea, Andreas Engert, MD, Peter Borchmann, MD, Bastian von Tresckow, MD, Teresa Halbsguth, MD, Karolin Behringer, MD, Diana Wongso, MD, Boris Böll, MD, Beate Klimm, MD, Indra Thielen, MD, Dennis A. Eichenauer, MD, Nicole Skoetz, MD
Journal: Blood
Blood (2012) 120 (21): 4230.
https://doi.org/10.1182/blood.V120.21.4230.4230
Published: 2012
Journal Articles

Outcome and Risk Factors of Hodgkin Lymphoma Patients with Relapse or Progression After Autologous Stem Cell Transplant: A Report From the German Hodgkin Study Group (GHSG).

Bastian von Tresckow, MD, Horst Müller, PhD, Dennis A. Eichenauer, MD, Jan Peter Glossmann, MD, Andreas Josting, MD, Boris Böll, MD, Beate Klimm, MD, Michael Fuchs, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2012) 120 (21): 2633.
https://doi.org/10.1182/blood.V120.21.2633.2633
Published: 2012
Journal Articles

Discrimination of an Early Unfavorable Risk Group Has Significant Impact On Treatment Outcome in Early-Stage Hodgkin Lymphoma: An Analysis of International Staging Definitions and Risk Factors

Beate Klimm, MD, Helen Goergen, Michael Fuchs, MD, Bastian von Tresckow, MD, Volker Diehl, MD, Hans Theodor Eich, MD, Andreas Engert, MD, Peter Borchmann, MD
Journal: Blood
Blood (2012) 120 (21): 54.
https://doi.org/10.1182/blood.V120.21.54.54
Published: 2012
Journal Articles

Treatment of Stage I-II A Non-Bulky Hodgkin's Lymphoma (HL): An Individual Patient-Data Comparison of German Hodgkin Study Group (GHSG) HD10 and HD11 Combined-Modality Therapy (CMT) and NCIC Clinical Trials Group (NCIC CTG) HD.6 ABVD Alone

Annette E. Hay, MBChB, Beate Klimm, MD, Bingshu E. Chen, PhD, Helen Goergen, Lois E. Shepherd, M.D., Michael Fuchs, MD, Mary Gospodarowicz, MD, Peter Borchmann, MD, Joseph M. Connors, MD, Jana Markova, MD, Michael Crump, MD, FRCPC, Andreas Lohri, MD, Jane N. Winter, MD, Bernd Dörken, Robert G. Pearcey, MD, Volker Diehl, MD, Sandra J. Horning, M.D., Hans Theodor Eich, MD, Andreas Engert, MD, Ralph M. Meyer, MD
Journal: Blood
Blood (2012) 120 (21): 548.
https://doi.org/10.1182/blood.V120.21.548.548
Published: 2012
Journal Articles

Phase II Study of Rituximab in Newly Diagnosed Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Report From the German Hodgkin Study Group (GHSG)

Dennis A. Eichenauer, MD, Michael Fuchs, MD, Annette Pluetschow, Beate Klimm, MD, Teresa Halbsguth, MD, Boris Böll, MD, Bastian von Tresckow, MD, Peter Borchmann, MD, Andreas Engert, MD
Journal: Blood
Blood (2011) 118 (21): 2711.
https://doi.org/10.1182/blood.V118.21.2711.2711
Published: 2011
Journal Articles

Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group

Brief Report
Dennis A. Eichenauer, Michael Fuchs, Annette Pluetschow, Beate Klimm, Teresa Halbsguth, Boris Böll, Bastian von Tresckow, Lucia Nogová, Peter Borchmann, Andreas Engert
Journal: Blood
Blood (2011) 118 (16): 4363–4365.
https://doi.org/10.1182/blood-2011-06-361055
Published: 2011
Journal Articles

Mortality during Treatment of Patients with Advanced Hodgkin’s Lymphoma Undergoing Dose Escalated BEACOPP Chemotherapy: An Analysis of the German Hodgkin Study Group (GHSG).

Michael Fuchs, Jeremy Franklin, Beate Klimm, Andreas Josting, Beate Pfistner, Andreas Engert, Volker Diehl
Journal: Blood
Blood (2005) 106 (11): 2668.
https://doi.org/10.1182/blood.V106.11.2668.2668
Published: 2005
Journal Articles

Leucopenia during Treatment Is a Good Prognostic Risk Factor for Patients Undergoing Chemotherapy for Hodgkin’s Lymphoma: An Analysis of the German Hodgkin Study Group (GHSG).

Beate Klimm, Thorsten Reineke, Heinz Haverkamp, Hans T. Eich, Karolin Behringer, Andreas Josting, Beate Pfistner, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2005) 106 (11): 2674.
https://doi.org/10.1182/blood.V106.11.2674.2674
Published: 2005
Journal Articles

The Superior Prognosis of Female Patients with Hodgkin’s Lymphoma Is Related to More Treatment-Induced Leucopenia and Warrants a More Individualized Therapy.

Beate Klimm, MD, Thorsten Reineke, Heinz Haverkamp, Hans T. Eich, MD, Andreas Josting, MD, Beate Pfistner, PhD, Volker Diehl, MD, Andreas Engert, MD
Journal: Blood
Blood (2004) 104 (11): 1313.
https://doi.org/10.1182/blood.V104.11.1313.1313
Published: 2004
Journal Articles

Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days.

Andreas Engert, Hartmut Doehner, Anthony D. Ho, Norbert Schmitz, Henning Bredenfeld, Dieter Hoelzer, Beate Klimm, Axel Muenz, Valerie Easton, Pamela Bacon, Volker Diehl
Journal: Blood
Blood (2004) 104 (11): 1316.
https://doi.org/10.1182/blood.V104.11.1316.1316
Published: 2004
Journal Articles

Secondary Amenorrhoea after Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives during Therapy: A Report from the German Hodgkin Lymphoma Study Group (GHSG).

Karolin Behringer, MD, Kai Breuer, MD, Thomas Reineke, MSc, Michael May, MD, Lucia Nogova, MD, Beate Klimm, MD, Volker Diehl, MD, Andreas Engert, MD
Journal: Blood
Blood (2004) 104 (11): 1314.
https://doi.org/10.1182/blood.V104.11.1314.1314
Published: 2004